This is why having both is so critical
L 114-158), and most recently re-authorized and extended by the Consolidated Appropriations Act of 2021 (Pub
Researched applications In the published preclinical and clinical literature the effects of Cagrilintide are documented in the following areas: Obesity (stand-alone) , Phase 2 data (Lau 2021, 10.8 % at 4.5 mg) Obesity + Semaglutide (CagriSema) , Phase 3 REDEFINE 1 (25.3 %) T2DM + obesity , Phase 3 REDEFINE 2 Cardiovascular prevention , Phase 3 REDEFINE 3 (n ~ 7000) MASLD/MASH , exploratory in Phase 2 Type 2 diabetes (monotherapy) , preclinical data Prediabetes , exploratory plans Science & studies 4.1 Key publications Lau D.C.W., Erichsen L., Francisco A.M., et al
You should always tell your provider about: Current medications and supplements Known allergies Pre-existing medical conditions When to contact your provider: If you experience a persistent headache, severe muscle weakness, or a rash that lasts longer than 24 hours, please call your provider
